{"version":"1.0","type":"link","title":"Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.","author_name":"Graff JN 외","author_url":"https://prs-insight.online/author/Graff%20JN","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/138713","thumbnail_width":1200,"thumbnail_height":630}